Experienced clinical development leader with over two decades of expertise across immuno-oncology, cell and gene therapy, neurology, and hematology. Proven success in designing and executing Phase I–IV global trials, authoring clinical protocols, and leading regulatory interactions. Adept in medical monitoring, safety assessments, and cross-functional collaboration, with deep understanding of CAR-T, TGF-β inhibitors, and checkpoint inhibitors. A trusted medical strategist with extensive experience managing key stakeholder relationships and clinical program execution.